{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T19:00:21Z","timestamp":1762974021221,"version":"3.45.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaccas.2022.04.015","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T17:20:07Z","timestamp":1655313607000},"page":"755-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Left Atrial Appendage Occlusion as\u00a0an\u00a0Alternative to Anticoagulants in\u00a0Ibrutinib-Induced Hemorrhagic Pericardial Effusion"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-0556","authenticated-orcid":false,"given":"Sergio","family":"Berti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto R.","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald D.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2022.04.015_bib1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaccas.2022.04.015_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(87)90174-7","article-title":"Risk of stroke in non-rheumatic atrial fibrillation","volume":"1","author":"Flegel","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jaccas.2022.04.015_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccas.2022.04.015_bib4","unstructured":"Ibrutinib (Ibruvica) [package insert]. Pharmacyclics, Inc.; 2015."},{"key":"10.1016\/j.jaccas.2022.04.015_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccas.2022.04.015_bib6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin \u03b1IIb\u03b23 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccas.2022.04.015_bib7","first-page":"751","article-title":"Left atrial appendage occlusion as an alternative to anticoagulants in Ibrutinib-induced hemorrhagic pericardial effusion","volume":"4","author":"Jeelani","year":"2022","journal-title":"J Am Coll Cardiol Case Rep"},{"key":"10.1016\/j.jaccas.2022.04.015_bib8","first-page":"1491","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jaccas.2022.04.015_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jaccas.2022.04.015_bib10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/heartjnl-2012-301799","article-title":"Importance of the underlying substrate in determining thrombus location in atrial fibrillation: implications for left atrial appendage closure","volume":"98","author":"Mahajan","year":"2012","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.jaccas.2022.04.015_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccas.2022.04.015_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccas.2022.04.015_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaccas.2022.04.015_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccas.2022.04.015_bib15","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccas.2022.04.015_bib16","first-page":"1170","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug","volume":"10","author":"Tzikas","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jaccas.2022.04.015_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcin.2019.02.003","article-title":"Incidence, characterization, and clinical impact of device-related thrombus following left atrial appendage occlusion in the prospective Global AMPLATZER Amulet observational study","volume":"12","author":"Aminian","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jaccas.2022.04.015_bib18","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.hrthm.2011.04.022","article-title":"TRENDS Investigators. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS","volume":"8","author":"Daoud","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccas.2022.04.015_bib19","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084922003266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084922003266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:49:22Z","timestamp":1762973362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084922003266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666084922003266"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2022.04.015","relation":{},"ISSN":["2666-0849"],"issn-type":[{"type":"print","value":"2666-0849"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Left Atrial Appendage Occlusion as\u00a0an\u00a0Alternative to Anticoagulants in\u00a0Ibrutinib-Induced Hemorrhagic Pericardial Effusion","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2022.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2022.01.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}